Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $39.52, for a total value of $790,400.00. Following the completion of the sale, the executive vice president directly owned 40,000 shares of the company’s stock, valued at approximately $1,580,800. The trade was a 33.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Marshall Urist also recently made the following trade(s):

• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total value of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total transaction of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Trading Down 1.2%

Shares of RPRX stock traded down $0.46 during mid-day trading on Tuesday, hitting $39.09. The company’s stock had a trading volume of 3,688,485 shares, compared to its average volume of 3,795,324. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $41.70. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The company has a market cap of $22.56 billion, a PE ratio of 29.61, a P/E/G ratio of 1.89 and a beta of 0.43. The company’s fifty day simple moving average is $39.31 and its 200-day simple moving average is $37.46.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. As a group, equities research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be paid a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 2.4%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s payout ratio is currently 66.67%.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. TD Cowen increased their target price on Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Saturday, October 25th. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 target price on the stock. Morgan Stanley cut their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Finally, Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.60.

Hedge Funds Weigh In On Royalty Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC raised its holdings in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. USA Financial Formulas bought a new position in shares of Royalty Pharma in the 2nd quarter worth about $32,000. Financial Consulate Inc. bought a new position in shares of Royalty Pharma during the third quarter worth about $35,000. Larson Financial Group LLC raised its position in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 306 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Royalty Pharma by 113.8% during the second quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 760 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.